Stagezero Life - SZLSF STOCK NEWS

StageZero Life Sciences will release its Q4 2021 and year-end operational results on April 1, 2022. A conference call hosted by Chairman and CEO James Howard-Tripp will follow at 8:30 a.m. EST. The call aims to discuss the operational results and future business developments. The company's mRNA multi-cancer panel, Aristotle, demonstrates high sensitivity in screening for multiple cancers. StageZero trades on the TSX under SZLS and OTCQB under SZLSF.

StageZero Life Sciences announced the availability of its Care Oncology Clinic service and COC Protocol to patients in Europe, extending its offerings beyond the UK, US, and Canada. This service aims to enhance cancer management through adjunctive treatments designed to boost the effectiveness of standard therapies. The COC Protocol is a personalized approach that focuses on the metabolic pathways of cancer cells. With Europe’s population around 750 million, the company expects significant growth and expansion opportunities in this new market.

StageZero Life Sciences has successfully completed a private placement, raising approximately CAD$1.87 million by issuing 10 million Common Shares and Warrants with an exercise price of CAD$0.2206. These funds will support the acceleration of its Global Growth Strategy and enhance the commercialization of its cancer screening products, including Aristotle and AVRT. The company aims to expand its market presence in the US, Canada, and the UK. H.C. Wainwright & Co. acted as the exclusive placement agent for this transaction.

StageZero Life Sciences has announced a private placement agreement with an institutional investor, aiming to raise approximately CAD$1.87 million through the issuance of 10 million common shares and warrants. Each share will sell for CAD$0.187, with warrants exercisable at CAD$0.2206 for four years. The funds will support the company’s Global Growth Strategy and enhance the commercialization of its diagnostics, including the Aristotle test. The placement is expected to close by March 2, 2022, pending customary conditions and approval from the Toronto Stock Exchange.

StageZero Life Sciences (TSX:SZLS / OTCQB:SZLSF) announced plans to extend the expiry date of 5,702,314 outstanding share purchase warrants to January 31, 2023. This decision responds to shareholder requests and aims to support past financing participants, potentially raising up to C$5.654 million if all warrants are exercised. The effective amendment date is set for February 18, 2022. StageZero focuses on early cancer detection and management through innovative diagnostics like Aristotle®, a multi-cancer blood test.

StageZero Life Sciences has formed a Scientific Advisory Board to enhance its mission of improving early cancer detection. Renowned experts Dr. Barry Boyd, Dr. Jason Fung, and Benjamin Bikman, Ph.D. join the board, bringing expertise in oncology, nephrology, and metabolic diseases. This board will evaluate the company’s research and development strategy critically. Furthermore, StageZero's proprietary test, Aristotle, is the first mRNA multi-cancer panel capable of simultaneous cancer screening from a single blood sample.

StageZero Life Sciences has been approved as a certified COVID-19 testing provider for travelers to Aruba from Canada and the U.S., collaborating with OK2Roam and VFS Global. This partnership enables travelers to easily schedule PCR tests online, with results sent directly to Aruban authorities, streamlining the entry process. StageZero stands out as a preferred Canadian provider and one of two U.S. healthcare providers for this testing service. The initiative aims to enhance travel safety and convenience amidst evolving pandemic regulations.

StageZero Life Sciences announces the appointment of SRCO Professional Corporation as its new auditors, replacing McGovern Hurley LLP, which resigned. The transition was approved by the Board without any reservations or reportable events. CFO Matthew Pietras expressed optimism about partnering with SRCO as the company aims for a stronger presence in the U.S. SRCO has experience with complex business operations, aligning with StageZero's goals. The company continues its collaboration with MNP LLP for financial statement preparation.